1
|
Don E, Zakharova S, Yaroshenko S, Petrova A, Tarasov S. Biological Medicines Prepared Using Vibration Processing Are Able to Influence Their Targets Without Direct Contact With Them. Dose Response 2024; 22:15593258241284704. [PMID: 39351077 PMCID: PMC11440525 DOI: 10.1177/15593258241284704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 07/12/2024] [Accepted: 08/20/2024] [Indexed: 10/04/2024] Open
Abstract
Recently, there has been a radical change in understanding of the nature of drugs based on highly diluted solutions. It has been established that their activity does not depend on the content of the original substance in dilutions, but is a consequence of the technological processing (TP) of dilutions with vibration, which accompanies each dilution during the preparation of solutions and, among others, leads to the formation of nanoparticles with certain properties. Repeated vibration treatment leads to the appearance of modifying activity that is absent in the original substance, and these effects of TP solutions can be exerted without direct contact with their targets, which clearly indicates the physical nature of the TP solution's activity. In the framework of this article, a statistically significant effect of TP antibodies to the insulin receptor on glucose consumption by CHO cells both with and without contact exposure, as compared with control (P < 0.05) was shown in the vast majority of the experiments. The obtained results shed light on a possible source of activity of drugs based on TP antibodies, which should be associated with the applied vibration effect and can manifest itself both with contact exposure and without it.
Collapse
Affiliation(s)
- Elena Don
- R&D Department, OOO «NPF «Materia Medica Holding», Moscow, Russian Federation
| | - Svetlana Zakharova
- R&D Department, OOO «NPF «Materia Medica Holding», Moscow, Russian Federation
| | - Sabina Yaroshenko
- R&D Department, OOO «NPF «Materia Medica Holding», Moscow, Russian Federation
| | - Anastasia Petrova
- R&D Department, OOO «NPF «Materia Medica Holding», Moscow, Russian Federation
| | - Sergey Tarasov
- R&D Department, OOO «NPF «Materia Medica Holding», Moscow, Russian Federation
- Laboratory of Physiologically Active Substances, Federal State Budgetary Scientific Institute of General Pathology and Pathophysiology, Moscow, Russian Federation
| |
Collapse
|
2
|
Mkrtumyan A, Ametov A, Demidova T, Volkova A, Dudinskaya E, Vertkin A, Vorobiev S. A New Approach to Overcome Insulin Resistance in Patients with Impaired Glucose Tolerance: The Results of a Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety of Subetta. J Clin Med 2022; 11:jcm11051390. [PMID: 35268481 PMCID: PMC8910875 DOI: 10.3390/jcm11051390] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Revised: 02/24/2022] [Accepted: 03/02/2022] [Indexed: 02/04/2023] Open
Abstract
Impaired glucose tolerance (IGT) is a common carbohydrate metabolism disorder world-wide. To evaluate the efficacy and safety of 12-week Subetta therapy in correcting 2-h plasma glucose in patients with IGT, a multicenter, double-blind, placebo-controlled, randomized clinical trial was performed. Derived by technological treatment of antibodies to insulin receptor β-subunit and endothelial NO synthase, Subetta increases the sensitivity of insulin receptors by activating the insulin signaling pathway. Oral glucose tolerance test (OGTT), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) were examined at screening, after 4 and 12 weeks. In Per Protocol population, 2-h plasma glucose in the Subetta group decreased by 2.05 ± 2.11 mmol/L (versus 0.56 ± 2.55 mmol/L in the Placebo group) after 12 weeks. The difference between the two groups was 1.49 ± 2.33 mmol/L (p < 0.0001). After 12 weeks, 65.2% of patients had 2-h plasma glucose <7.8 mmol/L. FPG remained almost unchanged. HbA1c tended to decrease. The number of adverse events did not differ in both groups. Subetta treatment is beneficial for patients with IGT; it also prevents progression of carbohydrate metabolism disorders.
Collapse
Affiliation(s)
- Ashot Mkrtumyan
- Department of Endocrinology, Moscow Clinical Scientific and Practical Center Named after A. S. Loginov, 111123 Moscow, Russia
- Department of Endocrinology and Diabetology, A. I. Evdokimov Moscow State University of Medicine and Dentistry, 127473 Moscow, Russia
- Correspondence: ; Tel.: +7-495-6096700
| | - Alexander Ametov
- Department of Endocrinology, Faculty of Medicine, Medical Academy of Continuing Professional Education, 125993 Moscow, Russia;
| | - Tatiana Demidova
- Department of Endocrinology, City Clinical Hospital Named after V. P. Demikhova, 117463 Moscow, Russia;
- Department of Endocrinology, Faculty of Medicine, Pirogov Russian National Research Medical University, 117997 Moscow, Russia
| | - Anna Volkova
- Department of Faculty Therapy, Faculty of Medicine, Pavlov First Saint Petersburg State Medical University, 197022 St. Petersburg, Russia;
| | - Ekaterina Dudinskaya
- Department of Age-Related Metabolic and Endocrine Disorders, Russian Gerontological Research and Clinical Center, Pirogov Russian National Research Medical University, 129226 Moscow, Russia;
| | - Arkady Vertkin
- Department of Therapy, Clinical Pharmacology and Emergency Medicine, A. I. Evdokimov Moscow State University of Medicine and Dentistry, 127473 Moscow, Russia;
- Department of Therapy, City Clinical Hospital Named after S.I. Spasokukotsky, 127006 Moscow, Russia
| | - Sergei Vorobiev
- Department of Endocrinology, Rostov State Medical University, 344022 Rostov-on-Don, Russia;
| |
Collapse
|
3
|
Andrianova E, Putilovskiy M. Efficacy and safety of Ergoferon versus oseltamivir: Reply to the Letter to the Editor. Int J Infect Dis 2019; 89:190-192. [PMID: 31626982 DOI: 10.1016/j.ijid.2019.09.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 09/26/2019] [Accepted: 09/27/2019] [Indexed: 10/25/2022] Open
Affiliation(s)
- Elena Andrianova
- Research and Development Department, Materia Medica Holding, Moscow, Russian Federation, Russia.
| | - Mikhail Putilovskiy
- Research and Development Department, Materia Medica Holding, Moscow, Russian Federation, Russia
| |
Collapse
|
4
|
Affiliation(s)
- Alexander Y Panchin
- Sector of Molecular Evolution, Institute for Information Transmission Problems, Russian Academy of Sciences, Moscow, Russia
| | - Nikita N Khromov-Borisov
- Department of the Mathematical Modeling and Analysis, Almazov National Medical Research Centre, Saint Petersburg, Russia
| | - Evgenia V Dueva
- Vancouver Prostate Centre, Department of Urologic Sciences, The University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
5
|
Mkrtumyan A, Romantsova T, Vorobiev S, Volkova A, Vorokhobina N, Tarasov S, Putilovskiy M, Andrianova E, Epstein O. Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Diabetes Res Clin Pract 2018; 142:1-9. [PMID: 29807102 DOI: 10.1016/j.diabres.2018.04.044] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 04/09/2018] [Accepted: 04/30/2018] [Indexed: 12/31/2022]
Abstract
BACKGROUND To examine efficacy of Subetta as an add-on to insulin therapy in patients with type 1 diabetes mellitus (T1DM) a multicenter, double-blind, placebo-controlled, randomized clinical trial was performed. Derived by technological treatment of antibodies to insulin receptor β-subunit and endothelial NO synthase Subetta was previously proved to activate insulin signaling pathway. METHODS A total of 144 randomized patients with poor glycemic control in basal-bolus insulin regime were included in intention-to-treat analysis in Subetta add-on therapy or placebo (n = 72 in both groups). Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), basal and prandial insulin doses, number of hypoglycemia episodes confirmed by self-monitoring of blood glucose were recorded for 36 weeks. RESULTS The baseline characteristics of subjects did not differ between the two groups. HbA1c mean (±standard deviation) change was -0.59 ± 0.99% (95% CI -0.84 to -0.37) after 36 weeks in Subetta (vs. -0.20 ± 1.14%; 95% CI -0.44 to 0.11 in placebo; p = 0.028). The rate of overall hypoglycemia events was 7.9 per patient year (95% CI 7.1-8.6) in Subetta group and 7.6 (95% CI 6.9-8.4) in Placebo group (p = 0.63). The basal and total insulin doses did not change at the end of 36 weeks in both groups. CONCLUSIONS Subetta add-on therapy boosting insulin activity and improving glycemic control in patients with T1DM is proved to be beneficial. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT01868594.
Collapse
Affiliation(s)
- Ashot Mkrtumyan
- Moscow Clinical Scientific and Practical Center named after A.S. Loginov, 86, Enthusiastov Sh., 111123 Moscow, Russian Federation.
| | - Tatyana Romantsova
- Sechenov First Moscow State Medical University, 8-2, Trubetskaya St., 119991 Moscow, Russian Federation.
| | - Sergei Vorobiev
- Rostov State Medical University, 29, Nakhichevan Per., 344022 Rostov-on-Don, Russian Federation.
| | - Anna Volkova
- Pavlov First Saint Petersburg State Medical University, 6-8, Lva Tolstogo St., 197022 Saint Petersburg, Russian Federation.
| | - Natalia Vorokhobina
- Elizavetinskaya Municipal Hospital, 14, Vavilovyh St., 195257 Saint Petersburg, Russian Federation.
| | - Sergey Tarasov
- OOO "NPF "MATERIA MEDICA HOLDING", 9, 3rd Samotyochny Per., 127473 Moscow, Russian Federation.
| | - Mikhail Putilovskiy
- OOO "NPF "MATERIA MEDICA HOLDING", 9, 3rd Samotyochny Per., 127473 Moscow, Russian Federation.
| | - Elena Andrianova
- OOO "NPF "MATERIA MEDICA HOLDING", 9, 3rd Samotyochny Per., 127473 Moscow, Russian Federation.
| | - Oleg Epstein
- The Institute of General Pathology and Pathophysiology, 8, Baltiyskaya St., 125315 Moscow, Russian Federation.
| |
Collapse
|
6
|
Chanon S, Durand C, Vieille-Marchiset A, Robert M, Dibner C, Simon C, Lefai E. Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes. J Vis Exp 2017. [PMID: 28671646 DOI: 10.3791/55743] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Skeletal muscle is the largest glucose deposit in mammals and largely contributes to glucose homeostasis. Assessment of insulin sensitivity of muscle cells is of major relevance for all studies dedicated to exploring muscle glucose metabolism and characterizing metabolic alterations. In muscle cells, glucose transporter type 4 (GLUT4) proteins translocate to the plasma membrane in response to insulin, thus allowing massive entry of glucose into the cell. The ability of muscle cells to respond to insulin by increasing the rate of glucose uptake is one of the standard readouts to quantify muscle cell sensitivity to insulin. Human primary myotubes are a suitable in vitro model, as the cells maintain many features of the donor phenotype, including insulin sensitivity. This in vitro model is also suitable for the test of any compounds that could impact insulin responsiveness. Measurements of the glucose uptake rate in differentiated myotubes reflect insulin sensitivity. In this method, human primary muscle cells are cultured in vitro to obtain differentiated myotubes, and glucose uptake rates with and without insulin stimulation are measured. We provide a detailed protocol to quantify passive and active glucose transport rates using radiolabeled [3H] 2-deoxy-D-Glucose ([3H]2dG). Calculation methods are provided to quantify active basal and insulin-stimulated rates, as well as stimulation fold.
Collapse
Affiliation(s)
| | | | | | - Maud Robert
- Department of digestive and bariatric surgery, Obesity Integrated Center, University Hospital of Edouard Herriot, Hospices Civils de Lyon, Lyon 1 University
| | - Charna Dibner
- Division of Endocrinology, Diabetes, Hypertension and Nutrition, Department of Clinical Medicine, Faculty of Medicine, University of Geneva
| | - Chantal Simon
- CarMeN Laboratory, INSERM U1060, INRA 1397, University of Lyon
| | - Etienne Lefai
- CarMeN Laboratory, INSERM U1060, INRA 1397, University of Lyon;
| |
Collapse
|
7
|
Ye L, Maji S, Sanghera N, Gopalasingam P, Gorbunov E, Tarasov S, Epstein O, Klein-Seetharaman J. Structure and dynamics of the insulin receptor: implications for receptor activation and drug discovery. Drug Discov Today 2017; 22:1092-1102. [PMID: 28476537 DOI: 10.1016/j.drudis.2017.04.011] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2016] [Revised: 04/16/2017] [Accepted: 04/19/2017] [Indexed: 01/05/2023]
Abstract
Recently, major progress has been made in uncovering the mechanisms of how insulin engages its receptor and modulates downstream signal transduction. Here, we present in detail the current structural knowledge surrounding the individual components of the complex, binding sites, and dynamics during the activation process. A novel kinase triggering mechanism, the 'bow-arrow model', is proposed based on current knowledge and computational simulations of this system, in which insulin, after its initial interaction with binding site 1, engages with site 2 between the fibronectin type III (FnIII)-1 and -2 domains, which changes the conformation of FnIII-3 and eventually translates into structural changes across the membrane. This model provides a new perspective on the process of insulin binding to its receptor and, thus, could lead to future novel drug discovery efforts.
Collapse
Affiliation(s)
- Libin Ye
- Department of Structural Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Suvrajit Maji
- Department of Structural Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Narinder Sanghera
- Division of Metabolic and Vascular Health & Systems, Medical School, University of Warwick, Coventry CV4 7AL, UK
| | - Piraveen Gopalasingam
- Division of Metabolic and Vascular Health & Systems, Medical School, University of Warwick, Coventry CV4 7AL, UK
| | - Evgeniy Gorbunov
- OOO 'NPF 'MATERIA MEDICA HOLDING', 47-1, Trifonovskaya St, Moscow 129272, Russian Federation
| | - Sergey Tarasov
- OOO 'NPF 'MATERIA MEDICA HOLDING', 47-1, Trifonovskaya St, Moscow 129272, Russian Federation
| | - Oleg Epstein
- The Institute of General Pathology and Pathophysiology, 8, Baltiyskaya St, 125315 Moscow, Russian Federation
| | - Judith Klein-Seetharaman
- Department of Structural Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA; Division of Metabolic and Vascular Health & Systems, Medical School, University of Warwick, Coventry CV4 7AL, UK.
| |
Collapse
|